Date: January 2, 2009
URL: http://www.google.com/patents/about?id=fw3UAAAAEBAJ
B-cell depleting agents, like anti-CD20 antibodies or fragments
thereof for the treatment of Chronic Fatigue Syndrome
---------------------------------------------------------------
Abstract
The present invention relates in a first aspect to a B-cell depleting
anti-CD20 antibody or a CD20-binding antibody fragment thereof for the
treatment of chronic fatigue syndrome and myalgic encephalomyelitis.
In particular, the present invention relates to the use of anti-CD20
monoclonal antibodies or fragments thereof which are preferably
humanized for the treatment of chronic fatigue syndrome/myalgic
encephalomyelitis in a subject afflicted with said disease.
Inventors
Olav Mella, Oystein Fluge
Current U.S. Classification
424/173.1; 530/387.3; 530/388.22; 530/389.6; 544/260
Claims
What is claimed is:
1. A B-cell depleting agent for the treatment of chronic fatigue
syndrome and myalgic encephalomyelitis.
2. The B-cell depleting agent according to claim 1, which is a B-cell
depleting anti CD20 antibody or CD20-binding antibody fragment thereof.
3. The B-cell depleting anti CD20 antibody or CD20-binding antibody
fragment according to claim 2, which is monoclonal antibody or
CD20-binding antibody fragment thereof.
4. The B-cell depleting agent according to claim 2, which is a
humanized anti CD20 antibody or CD20-binding antibody fragment thereof.
5. The B-cell depleting agent according to claim 2, which is a B-cell
depleting CD20 antibody fragment binding to CD20, preferably an
antigen binding fragment selected from the group consisting of
F(ab?)2, F(ab?), Fab, Fv and sFv.
6. The B-cell depleting agent according to claim 1 which is selected
from the humanized antibodies Rituximab. Ofatumumab, Ocrelizumab,
GA101, BCX-301, Veltuzumab or DXL 625.
7. The B-cell depleting agent according to claim 1, which is
Methotrexat TRU-015 or SBI-087.
8. A B-cell depleting agent according to claim 1, for the treatment of
chronic fatigue syndrome/myalgic encephalomyelitis wherein the amount
of the B-cell depleting anti CD20 antibody is in the range of 10 mg to
5000 mg per dosage.
9. The B-cell depleting agent according to claim 1, wherein the B-cell
depleting agent is a B-cell depleting anti CD20 antibody or
CD20-binding antibody fragment thereof for the administration to a
subject in a single therapeutically effective dosage of said antibody
of 50 to 2000 mg/m2 or multiple of therapeutically effective dosages
of said anti CD20 antibody or anti CD20-binding antibody fragment
thereof of 50 to 2000 mg/m2.
10. A method of treating chronic fatigue syndrome and myalgic
encephalomyelitis comprising the step of administering a B-cell
depleting agent as defined in claim 1 to a subject afflicted therewith.
11. A method for treating chronic fatigue syndrome and myalgic
encephalomyelitis comprising the step of administering one or two
infusions twice within two weeks of a B-cell depleting agent as
defined in claim 1.
12. A method of treating chronic fatigue syndrome and myalgic
encephalomyelitis according to claim 10 whereby a combination of a
B-cell depleting anti CD20 antibody or CD20-binding antibody fragment
thereof with Methotrexat is administered simultaneously, separately or
sequentially to a subject suffering from chronic fatigue syndrome or
myalgic encephalomyelitis.
13. The use of a B-cell depleting agent according to claim 1 for the
treatment of chronic fatigue syndrome or myalgic encephalomyelitis.
14. A method of treating chronic fatigue syndrome and myalgic
encephalomyelitis according to claim 11 whereby a combination of a
B-cell depleting anti CD20 antibody or CD20-binding antibody fragment
thereof with Methotrexat is administered simultaneously, separately or
sequentially to a subject suffering from chronic fatigue syndrome or
myalgic encephalomyelitis.
--------
(c) 2011 Google
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
